Animal studies utilizing rodent models have shown that GSH supplementation can attenuate liver injury and enhance the degradation of unwanted cellular materials, making it a compelling therapeutic option for mitigating NAFLD disease progression [30,31,32,33]
To overexpress HNF4 and SAA genes, pcDNA3 vector (ThermoFisher Scientific) and pcDNA3 cDNA ORF clones of HNF4 (OHu25290D), MAT1A (OHu18604D), BHMT (OHu17861), CBS (OHu26151), and CDO1 (OHu17128) from Genscript USA were transiently transfected into the indicated cells with Lipofectamine 3000 (ThermoFisher Scientific)
Chosen by patients focused on recovery, performance, or post-procedure healing
NAFLD is estimated to affect 25% of the population worldwide [81] but, to date, there are no specific therapies available for the treatment [82], although some pharmacological strategies used for related disorder (e.g., diabetes) are also recommended for the treatment of NAFLD patients [79]
10:e00911